Clinical trial Recruiting at 1 site Observational Ages 19 and up

Evaluating a new stent for diabetic patients with coronary artery disease

Official title: A Prospective, Multicenter Observational Study of Efficacy and Safety of Polymer-free Amphilimus-eluting Stent (Cre8™/Cre8™ EVO) in Patients With Coronary Artery Disease According to the Presence of Diabetes Mellitus

Run by Korea University Anam Hospital · NCT05759676 · Data updated 2026-11-12

This study is testing a new type of stent for people with diabetes who have heart artery problems to see if it works better and is safer than traditional stents.

More Coronary Artery Disease trials

Quick facts

Study typeObservational
Ages19 Years and up
SexAll
Enrollment1800 (estimated)
SponsorKorea University Anam Hospital
Academic / other
Locations1 site (Seoul)
StatusRecruiting
StartedMarch 9, 2023
Main results expectedAugust 31, 2026
Study endsDecember 31, 2026
Registry record updatedApril 4, 2024
Trial IDNCT05759676 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 19 or older with diabetes who require coronary angioplasty and have consented to participate.

Probably not a fit

Patients with known hypersensitivity to the stent materials or those who are pregnant or planning surgery that would require stopping antiplatelet drugs may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study assesses the efficacy and safety of the polymer-free Amphilimus-eluting Cre8Evo stent in patients with diabetes mellitus undergoing coronary angioplasty. The Cre8Evo stent is designed to minimize inflammatory responses and reduce the risk of stent thrombosis, offering potential advantages over traditional drug-eluting stents. The study aims to evaluate its performance in preventing late proliferation of vascular smooth muscle cells in diabetic patients compared to other stent options. Participants will be monitored for clinical outcomes following stent placement.

Why it matters

Potential benefit: If successful, this study could lead to improved treatment outcomes for diabetic patients with coronary artery disease by reducing complications associated with stent placement.

How similar studies have gone: Previous studies have shown promising results for the Cre8Evo stent in diabetic patients, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age 19 or older

  * Patients who agreed to the research protocol and clinical follow-up plan, voluntarily decided to participate in this study, and gave written consent to the consent form ③ Patients who underwent coronary angioplasty by inserting Cre8™ or Cre8™ EVO stent for coronary artery disease for a lesion confirmed within the last 1 month

Exclusion Criteria:

* Patients with known hypersensitivity or contraindications to the following drugs or substances: heparin, aspirin, clopidogrel, amphilimus, cobalt chrome, stainless steel nickel, 316L metal, and contrast media If it can be controlled by pheniramine and pheniramine, registration is possible, but if there is known anaphylaxis, it is excluded.)

  * Pregnant women, lactating women, or women of childbearing age who are planning to become pregnant during the study period ③ Patients who are planning surgery to stop antiplatelet drugs within 12 months from registration

    * Patients whose remaining life expectancy is expected to be less than 1 year

      * Patients who visited the hospital due to cardiogenic shock and are predicted to have a low survival rate based on medical judgment ⑥ Subjects participating in medical device randomization research ⑦ Patients who underwent surgery using a stent other than Cre8™/Cre8™ EVO at the time of registration

Where it's running

  • Korea University Anam Hospital
    Seoul, South Korea
    Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.